***Background.*** Group B Streptococcus (GBS) is not just the primary cause of sepsis in neonates anymore. It is also becoming an increasingly important cause of morbidity and mortality in adults. The rise of GBS infections globally is not new and has been reported over the past few decades. However with the marked increase of cardiovascular disease and diabetes over the last several years, which are both serious risk factors for GBS infection, along with fewer antibiotics being available for treatment due to growing antimicrobial resistance, the rise in cases could grow exponentially. This study aims to better understand the current rates, risk factors, outcomes, and resistance patterns of GBS bacteremia.

***Methods.*** This is a retrospective study using electronic medical records of non-pregnant patients \>16 years of age with positive *Streptococcus agalactiae* bloodstream infections collected from the Inova Health system in Northern Virginia from 2011-2013.

***Results.*** 113 cases of positive *Streptococcus agalactiae* were identified from 2011-2013, with 21% (24/113) of them being recurrent cases. The average number of episodes per year was 38. The average age of patients was 63.9 years with a range of ages 18-94, of which 59% (67/113) were male, and 41% (46/113) were female. In 66% of cases, the infection source was without focus. The remaining cases had infectious sources associated with pneumonia, cellulitis, osteomyelitis, septic arthritis, infective endocarditis, and pyelonephritis, and 7% of patients presented with septic shock. The most common co-morbidities included hypertension, diabetes mellitus, and coronary artery disease. Mortality rate in this group was 15% (17/113) and the most common resistant antibiotics included tetracycline (61%), erythromycin (39%), clindamycin (31%), azithromycin (31%), and clarithromycin (31%).

***Conclusion.*** GBS infections continue to rise, particularly in patients with significant co-morbidities leading to recurrent infections, amputations, or even death. Antibiotic resistance is increasing, and currently there are only a few options available for treatment. Therefore, it is imperative that more attention be placed on the prevention and treatment of GBS infections.
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